Langues

Publications

Neurolixis is a science-driven company and places high priority on characterizing its drug development candidates (NLX-112 and NLX-101) in rigorously-conducted pharmacological studies. The results from these studies are reported in reputable international peer-reviewed neuroscience and pharmacology journals.
Note: NLX-112 was previously known as F13640 (befiradol) and NLX-101 was previously known as F15599.

To see over 40 publications on NLX-112 and NLX-101 see PubMed database (from US National Library of Medicine): complete list of publications

For abstracts of key publications (and some free PDFs of the full articles) see the links below.

 

Selected Publications on NLX-112:

The novel 5-HT1A receptor agonist, NLX-112, reduces L-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A
Neuropharmacology. 2016 Jan 8. pii: S0028-3908(16)30013-2. doi: 10.1016/j.neuropharm.2016.01.013.

 

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A
Exp Neurol. 2015 May 30. doi: 10.1016/j.expneurol.2015.05.021

 

In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and post-synaptic 5-HT1A receptors in the rat.

Lladò-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Psychopharmacology (Berl). 2012 May;221(2):261-72. Epub 2011 Dec 3.

 

Dual hyperalgesic and analgesic effects of the high-efficacy 5-HT1A agonist F13640: relationship with receptor occupancy and kinetic parameters.

Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC.
J Pharmacol Exp Ther. 2005 Mar;312(3):1034-42. Epub 2004 Nov 4.    Free PDF  pdf_symbol

 

Selected Publications on NLX-101:

Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study (free PDF).

Becker G, Bolbos R, Costes N, Redouté J, Newman-Tancredi A, Zimmer L
Sci Rep. 2016 May 23;6:26633. doi: 10.1038/srep26633.    Free PDF  pdf_symbol

 

Pinpointing brain stem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists

Ana P. Abdala, John Bissonnette, Adrian Newman-Tancredi,
Frontiers in Physiology 5: 205, 2014. doi: 10.3389/fphys.2014.00205   Free PDF  pdf_symbol

 

A selective 5-HT1A receptor agonist improves respiration in a mouse model of Rett syndrome.

Levitt ES, Hunnicutt BJ, Knopp SJ, Williams JT, Bissonnette JM.
J Appl Physiol (1985). 2013 Dec;115(11):1626-33. Epub 2013 Oct 3.

 

Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. 

Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, BruinsSlot L, Colpaert F, Vacher B, Cussac D.
Br J Pharmacol. 2009 Jan;156(2):338-53. Epub 2009 Jan 12.    Free PDF  pdf_symbol

 

Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors.

Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Br J Pharmacol. 2010 Aug;160(8):1929-40.     Free PDF  pdf_symbol

 

F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.

Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A.,
Eur Neuropsychopharmacol. 2010 Sep;20(9):641-54.

 

Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders.

Newman-Tancredi A,
Neuropsychiatry, April 2011, Vol. 1, No. 2, Pages 149-164.